npj aging最新文献_第4页

Switch of innate to adaptative immune responses in the brain of patients with Alzheimer's disease correlates with tauopathy progression. 阿尔茨海默病患者大脑中先天性免疫反应向适应性免疫反应的转换与牛磺酸病的进展有关。

npj aging Pub Date : 2024-03-18 DOI: 10.1038/s41514-024-00145-5

Marcos R Costa

引用次数: 0

Novel protective effect of the FOXO3 longevity genotype on mechanisms of cellular aging in Okinawans. FOXO3 长寿基因型对冲绳人细胞衰老机制的新保护作用。

IF 4.1

npj aging Pub Date : 2024-03-08 DOI: 10.1038/s41514-024-00142-8

Trevor H Torigoe, D Craig Willcox, Michio Shimabukuro, Moritake Higa, Mariana Gerschenson, Anastasia Andrukhiv, Makoto Suzuki, Brian J Morris, Randi Chen, Greg S Gojanovich, Richard C Allsopp, Bradley J Willcox

{"title":"Novel protective effect of the FOXO3 longevity genotype on mechanisms of cellular aging in Okinawans.","authors":"Trevor H Torigoe, D Craig Willcox, Michio Shimabukuro, Moritake Higa, Mariana Gerschenson, Anastasia Andrukhiv, Makoto Suzuki, Brian J Morris, Randi Chen, Greg S Gojanovich, Richard C Allsopp, Bradley J Willcox","doi":"10.1038/s41514-024-00142-8","DOIUrl":"10.1038/s41514-024-00142-8","url":null,"abstract":"The genetic association of FOXO3 genotypes with human longevity is well established, although the mechanism is not fully understood. We now report on the relationship of the FOXO3 longevity variant rs2802292 with telomere length, telomerase activity, FOXO3 expression, and inflammatory cytokine levels in men and women. In agreement with earlier work, the FOXO3 longevity variant conferred protection against telomere shortening of peripheral blood mononuclear cells from adults aged 55 years and older. This was accompanied by higher levels of telomerase activity in mononuclear cells for carriers of the longevity-associated FOXO3 G-allele of SNP rs2802292 (P = 0.015). FOXO3 mRNA expression increased slightly with age in both young (P = 0.02) and old (P = 0.08) G-allele carriers. Older female G-allele carriers displayed a modest decline in levels of pro-inflammatory cytokine IL-6 with age (P = 0.07). In contrast, older male G-allele carriers displayed an age-dependent increase in levels of anti-inflammatory cytokine IL-10 with age (P = 0.04). Thus, FOXO3 may act through several different pro-longevity mechanisms, which may differ by age and sex.","PeriodicalId":94160,"journal":{"name":"npj aging","volume":"10 1","pages":"18"},"PeriodicalIF":4.1,"publicationDate":"2024-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10923797/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140066404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects of ageing and frailty on circulating monocyte and dendritic cell subsets. 衰老和虚弱对循环单核细胞和树突状细胞亚群的影响。

npj aging Pub Date : 2024-03-04 DOI: 10.1038/s41514-024-00144-6

Rosanne D Reitsema, Ashok K Kumawat, Bernd-Cornèl Hesselink, Debbie van Baarle, Yannick van Sleen

{"title":"Effects of ageing and frailty on circulating monocyte and dendritic cell subsets.","authors":"Rosanne D Reitsema, Ashok K Kumawat, Bernd-Cornèl Hesselink, Debbie van Baarle, Yannick van Sleen","doi":"10.1038/s41514-024-00144-6","DOIUrl":"10.1038/s41514-024-00144-6","url":null,"abstract":"Ageing is associated with dysregulated immune responses, resulting in impaired resilience against infections and low-grade inflammation known as inflammageing. Frailty is a measurable condition in older adults characterized by decreased health and physical impairment. Dendritic cells (DCs) and monocytes play a crucial role in initiating and steering immune responses. To assess whether their frequencies and phenotypes in the blood are affected by ageing or frailty, we performed a flow cytometry study on monocyte and DC subsets in an immune ageing cohort. We included (n = 15 in each group) healthy young controls (HYC, median age 29 years), healthy older controls (HOC, 73 years) and Frail older controls (76 years). Monocyte subsets (classical, intermediate, non-classical) were identified by CD14 and CD16 expression, and DC subsets (conventional (c)DC1, cDC2, plasmacytoid (p)DC) by CD11c, CD1c, CD141 and CD303 expression. All subsets were checked for TLR2, TLR4, HLA-DR, CD86, PDL1, CCR7 and CD40 expression. We observed a lower proportion of pDCs in HOC compared to HYC. Additionally, we found higher expression of activation markers on classical and intermediate monocytes and on cDC2 in HOC compared to HYC. Frail participants had a higher expression of CD40 on classical and non-classical monocytes compared to the HOC group. We document a substantial effect of ageing on monocytes and DCs. Reduced pDCs in older people may underlie their impaired ability to counter viral infections, whereas enhanced expression of activation markers could indicate a state of inflammageing. Future studies could elucidate the functional consequences of CD40 upregulation with frailty.","PeriodicalId":94160,"journal":{"name":"npj aging","volume":"10 1","pages":"17"},"PeriodicalIF":0.0,"publicationDate":"2024-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10912203/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140029871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Your move: A precision medicine framework for physical activity in aging. 你的运动老龄体育活动的精准医学框架。

npj aging Pub Date : 2024-02-27 DOI: 10.1038/s41514-024-00141-9

Adrián Noriega de la Colina, Timothy P Morris, Arthur F Kramer, Navin Kaushal, Maiya R Geddes

引用次数: 0

Accelerated elastin degradation by age-disease interaction: a common feature in age-related diseases. 年龄-疾病相互作用加速弹性蛋白降解：老年相关疾病的共同特征。

npj aging Pub Date : 2024-02-27 DOI: 10.1038/s41514-024-00143-7

Naomi Shek, Anna-Maria Choy, Chim C Lang, Bruce E Miller, Ruth Tal-Singer, Charlotte E Bolton, Neil C Thomson, James D Chalmers, Matt J Bown, David E Newby, Faisel Khan, Jeffrey T J Huang

引用次数: 0

Author Correction: Senotherapeutic peptide treatment reduces biological age and senescence burden in human skin models. 作者更正：衰老治疗肽可降低人体皮肤模型的生物年龄和衰老负担。

npj aging Pub Date : 2024-02-15 DOI: 10.1038/s41514-024-00140-w

Alessandra Zonari, Lear E Brace, Kallie Al-Katib, William F Porto, Daniel Foyt, Mylieneth Guiang, Edgar Andres Ochoa Cruz, Bailey Marshall, Melissa Gentz, Gabriela Rapozo Guimarães, Octavio L Franco, Carolina R Oliveira, Mariana Boroni, Juliana L Carvalho

引用次数: 0

Cost of care for Alzheimer's disease and related dementias in the United States: 2016 to 2060. 美国阿尔茨海默病及相关痴呆症的护理成本：2016 年至 2060 年。

npj aging Pub Date : 2024-02-08 DOI: 10.1038/s41514-024-00136-6

Arindam Nandi, Nathaniel Counts, Janina Bröker, Sabrina Malik, Simiao Chen, Rachael Han, Jessica Klusty, Benjamin Seligman, Daniel Tortorice, Daniel Vigo, David E Bloom

{"title":"Cost of care for Alzheimer's disease and related dementias in the United States: 2016 to 2060.","authors":"Arindam Nandi, Nathaniel Counts, Janina Bröker, Sabrina Malik, Simiao Chen, Rachael Han, Jessica Klusty, Benjamin Seligman, Daniel Tortorice, Daniel Vigo, David E Bloom","doi":"10.1038/s41514-024-00136-6","DOIUrl":"10.1038/s41514-024-00136-6","url":null,"abstract":"Medical and long-term care for Alzheimer's disease and related dementias (ADRDs) can impose a large economic burden on individuals and societies. We estimated the per capita cost of ADRDs care in the in the United States in 2016 and projected future aggregate care costs during 2020-2060. Based on a previously published methodology, we used U.S. Health and Retirement Survey (2010-2016) longitudinal data to estimate formal and informal care costs. In 2016, the estimated per patient cost of formal care was $28,078 (95% confidence interval [CI]: $25,893-$30,433), and informal care cost valued in terms of replacement cost and forgone wages was $36,667 ($34,025-$39,473) and $15,792 ($12,980-$18,713), respectively. Aggregate formal care cost and formal plus informal care cost using replacement cost and forgone wage methods were $196 billion (95% uncertainty range [UR]: $179-$213 billion), $450 billion ($424-$478 billion), and $305 billion ($278-$333 billion), respectively, in 2020. These were projected to increase to $1.4 trillion ($837 billion-$2.2 trillion), $3.3 trillion ($1.9-$5.1 trillion), and $2.2 trillion ($1.3-$3.5 trillion), respectively, in 2060.","PeriodicalId":94160,"journal":{"name":"npj aging","volume":"10 1","pages":"13"},"PeriodicalIF":0.0,"publicationDate":"2024-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10853249/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139708909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mitochondrial function in peripheral blood cells across the human lifespan. 人一生中外周血细胞的线粒体功能。

npj aging Pub Date : 2024-02-07 DOI: 10.1038/s41514-023-00130-4

Johannes K Ehinger, Emil Westerlund, Eleonor Åsander Frostner, Michael Karlsson, Gesine Paul, Fredrik Sjövall, Eskil Elmér

引用次数: 0

Senolytics: from pharmacological inhibitors to immunotherapies, a promising future for patients' treatment. 衰老剂：从药理抑制剂到免疫疗法，患者治疗的美好未来。

IF 4.1

npj aging Pub Date : 2024-02-06 DOI: 10.1038/s41514-024-00138-4

V Lelarge, R Capelle, F Oger, T Mathieu, B Le Calvé

{"title":"Senolytics: from pharmacological inhibitors to immunotherapies, a promising future for patients' treatment.","authors":"V Lelarge, R Capelle, F Oger, T Mathieu, B Le Calvé","doi":"10.1038/s41514-024-00138-4","DOIUrl":"10.1038/s41514-024-00138-4","url":null,"abstract":"The involvement of cellular senescence in the initiation and propagation of diseases is clearly characterized, making the elimination of senescent cells essential to treat age-related diseases. The development of senolytic drugs demonstrated that targeting these cells limits the deterioration of patients' condition, by inducing apoptosis. Nevertheless, the first generations of senolytics which has been developed displayed their activities through specific mechanisms and demonstrated several limitations during clinical development. However, the rational to eliminate senescent cells remains evident, with the necessity to develop specific therapies in a context of diseases and tissues. The evolutions in the field of drug discovery open the way to a new generation of senolytic therapies, such as immunological approaches (CAR-T cells, Antibody-Drug Conjugated or vaccines), which require preliminary steps of research to identify markers specifically expressed on senescent cells, demonstrating promising specific effects. Currently, the preclinical development of these strategies appears more challenging to avoid strong side effects, but the expected results are commensurate with patients' hopes for treatments. In this review, we highlight the fact that the classical senolytic approach based on drug repurposing display limited efficacy and probably reached its limits in term of clinical development. The recent development of more complex therapies and the extension of interest in the domain of senescence in different fields of research allow to extend the possibility to discover powerful therapies. The future of age-related diseases treatment is linked to the development of new approaches based on cell therapy or immunotherapy to offer the best treatment for patients.","PeriodicalId":94160,"journal":{"name":"npj aging","volume":"10 1","pages":"12"},"PeriodicalIF":4.1,"publicationDate":"2024-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10847408/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139699177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

On the past, present and future of senotherapeutics. 关于老年疗法的过去、现在和未来。

npj aging Pub Date : 2024-02-03 DOI: 10.1038/s41514-024-00139-3

Marco Quarta, Marco Demaria

引用次数: 0